

Thursday, 13 October

**8:30 - 9:15**      **Plenary Lecture 1**  
**Autophagy: Its Molecular Machinery and Implications in Diseases**  
**Tamotsu YOSHIMORI**, Osaka University Graduate School of Medicine,  
 Department of Genetics, Japan

**9:15 - 12:00**    **Session 4: Pathogenesis**  
*Chairs: Mark HARRIS & Kyoko KOHARA*

- |                      |  |             |
|----------------------|--|-------------|
| <b>9:15 - 9:30</b>   | <b>Lipoprotein lipase inhibits hepatitis C virus infection and reverses virus-induced lipid accumulation through unsaturated fatty acid/CD36/PPARalpha signaling pathway</b><br><i>Sun HUNG-YU, Young KUNG-CHIA</i>  | <b>O-28</b> |
| <b>9:30 - 9:45</b>   | <b>PLA2G4C is involved in HCV induced lipid droplet accumulation</b><br><i>Masahiko ITO, Masayoshi FUKASAWA, Michinori KOHARA, Tetsuro SUZUKI</i>  | <b>O-29</b> |
| <b>9:45 - 10:00</b>  | <b>Resistin reinforces interferon <math>\lambda</math> -3 to eliminate hepatitis C virus with fine-tuning from RETN single nucleotide polymorphisms</b><br><i>Ming-Ling CHANG, Kung Hao LIANG, Chau-Ting YEH, Cheng-Tang CHIU</i>  | <b>O-30</b> |
| <b>10:00 - 10:15</b> | <b>HCV suppresses autophagosome degradation by Arl8b-mediated lysosomal repositioning</b><br><i>Steven A WEINMAN, Kellyann JONES-JAMTGAARD, Robert RALSTON, Ann L WOZNIAK</i>  | <b>O-31</b> |
| <b>10:15 - 10:30</b> | <b>Iron chelation restores mitophagy suppressed by hepatitis C virus</b><br><i>Yuichi HARA, Izumi YANATORI, Tasuku HIRAYAMA, Hideko NAGASAWA, Humio KISHI, Keisuke HINO</i>  | <b>O-32</b> |
| <b>10:30 - 11:00</b> | <b>Refreshment Break</b>   |             |
| <b>11:00 - 11:15</b> | <b>Retinoid Regulation of HCV Replication in Hepatocytes</b><br><i>Takeshi SAITO, Bo Ram BANG</i>  | <b>O-33</b> |
| <b>11:15 - 11:30</b> | <b>HCV stimulates exosome secretion via cleavage of the trafficking adaptor protein RILP</b><br><i>Ann L WOZNIAK, Abby LONG, Steven A WEINMAN</i>  | <b>O-34</b> |
| <b>11:30 - 11:45</b> | <b>miR-135a-5p-mediated downregulation of protein-tyrosine phosphatase delta is a candidate driver of HCV-associated hepatocarcinogenesis that acts by promoting STAT3 transcriptional activity</b><br><i>Joachim LUPBERGER, Nicolaas VAN RENNE, Armando A. ROCA SUAREZ, Francois H.T. DUONG, Claire GONDEAU, Diego CALABRESE, Nelly FONTAINE, Patrick PESSAUX, Markus H. HEIM, Thomas F. BAUMERT, Joachim LUPBERGER</i> | <b>O-35</b> |

**11:45 - 12:00**    **Hepatitis C virus induces host genome alterations through dysregulation of structural maintenance of chromosome complexes**    **O-36**

Meital GAL-TANAMY, Shira PEREZ, Michael GEVOR, Antony KASPI, Ateret DAVIDOVICH, Izhak HAVIV, Itay ONN

**12:00 - 12:15**    **Refreshment Break**

**12:15 - 13:25**    **Luncheon Seminar 2**

*Chairs: Takaji WAKITA, Department of Virology II, National Institute of Infectious Diseases*

*Hiroyuki MARUSAWA, Department of Gastroenterology and Hepatology, Graduate School of Medicine Kyoto University*

**Exploring a new era of HBV research by the influence of prior HCV research**

**Kunitada SHIMOTOHNO**, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine

**Basic and clinical perspectives in innate immunity during HCV infection**

**Masao HONDA**, Department of Laboratory Medicine and Technology, Graduate School of Medical Science, Kanazawa University

Sponsored by AbbVie GK

**13:25 - 14:45**    **Lunch**

**14:45 - 15:15**    **Keynote Lecture 4**

**Addressing the next challenges in virus-host interactions and liver disease**

**Thomas F BAUMERT**, Inserm, U1110, Institute of Viral and Liver Diseases, Strasbourg, University of Strasbourg, Center of Digestive Diseases and Hepatology and IHU, Strasbourg University Hospitals, France

**15:15 - 18:00**    **Session 5: Clinical research**

*Chairs: Nobuyuki ENOMOTO & Robert THIMME*

**15:15 - 15:30**    **Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals**    **O-37**

Elena PERPIÑÁN, Noelia CARO-PÉREZ, Josep GREGORI, Patricia GONZÁLEZ, Sabela LENS, Zoe MARIÑO, Concepción BARTRES, George KOUTSOUDAKIS, Josep QUER, Xavier FORNS, Sofía PÉREZ-DEL-PULGAR

**15:30 - 15:45**    **Deep Sequencing of Variants Resistant to Daclatasvir and Asunaprevir in HCV-1b Hepatitis**    **O-38**

Mitsuaki SATO, Shinya MAEKAWA, Natsuko NAKAKUKI, Shuya MATSUDA, Masaru MURAOKA, Yuichiro SUZUKI, Yasuhiro NAKAYAMA, Taisuke INOUE, Minoru SAKAMOTO, Nobuyuki ENOMOTO

15:45 - 16:00	<b>Resistance Characterization of Ledipasvir in Patients with HCV Genotype 4 Infection</b> <u>Gregory CAMUS</u> , Bin HAN, Hadas DVORY-SOBOL, Julia LU, Ross MARTIN, Evguenia SVAROVSKAIA, Wen OUYANG, Bandita PARHY, Karin KU, Michael MILLER, Armand ABERGEL, Tarik ASSELAH, Kathryn KERSEY, Diana M BRAINARD, Hongmei MO	O-39
16:00 - 16:15	<b>Reduction in Sofosbuvir and Ribavirin sensitivity in Genotype 3 Hepatitis C Virus from patients who relapse to all oral therapy</b> <u>Peter WING</u> , Ana FILIPE, Morven E CUNNINGHAM, Sampath DE SILVA, Michelle CHEUNG, Meleri JONES, Will IRVING, John MCLAUHLAN, Graham R FOSTER	O-40
16:15 - 16:30	<b>Outcomes and Predictors of Treatment Failure to Direct Acting Antivirals in Chronically Infected Patients with Severe Liver Disease</b> <u>John MCLAUHLAN</u> , Ana DA SILVA FILIPE, Michelle CM CHEUNG, Elihu ARANDAY-CORTES, Josh SINGER, Vattipally SREENU, Kosh AGARWAL, William IRVING, Emma C THOMSON, Graham R FOSTER, On behalf of HCV RESEACH UK	O-41
16:30 - 16:45	<b>Efficacy and safety of IFN-free direct acting antivirals therapy for patients with renal impairment</b> <u>Goki SUDA</u> , Seiji TSUNEMATSU, Masato NAKAI, Takuya SHO, Kenichi MORIKAWA, Koji OGAWA, Naoya SAKAMOTO	O-42
16:45 - 17:00	<b>Investigation of Occult HCV Infection in DAA treated post-OLT Subject</b> <u>Takeshi SAITO</u> , Sanya WADHWA, Sandra ELMASRY, Bo Ram BANG, Brian KIM, Gary KANEL, Shefali CHOPRA, Cook LINDA, Keith JEROME, Tammy HARPER, Jeffrey KAHN	O-43
17:00 - 17:15	<b>Identification of the micro RNA associated with elimination of hepatitis C virus by daclatasvir plus asunaprevir therapy</b> <u>Hirohito YONEYAMA</u> , Joji TANI, Hisakazu IWAMA, Asahiro MORISHITA, Koji FUJITA, Hisakazu MIYOSHI, Takako NOMURA, Teppei SAKAMOTO, Tomoko TADOKORO, Kyoko OURA, Tsutomu MASAKI	O-44
17:15 - 17:30	<b>Pre-treatment NK cell phenotype differs between HCV patients with sustained virological response and those with viral breakthrough to antiviral therapy</b> <u>Elisavet SERTI</u> , Marc GHANY, Barbara REHERMANN	O-45
17:30 - 17:45	<b>A divergent hepatitis C virus (HCV) strain may represent a new major HCV genotype (Genotype 8)</b> <u>Anders WIDELL</u> , Ola FORSLUND, Patrik MEDSTRAND	O-46
17:45 - 18:00	<b>HCVGenoTyper: A computer program for accurate hepatitis C virus genotyping using high throughput sequences</b> <u>Bala Sreenu VATTIPALLY</u> , Emma C THOMSON	O-47
18:00 - 18:30	<b>Refreshment Break</b>	
18:30 - 20:30	<b>Poster Session 2</b>	